Key result
Factor XI/XIa inhibitors offer potential advantages over DOACs in stroke prevention, such as reduced bleeding and fewer drug interactions, though clinical trials must still demonstrate non-inferiority.
Why the study?
Standard of care antithrombotic therapies are underutilized and limited by bleeding rates, drug interactions, and renal elimination, creating interest in FXI/XIa inhibitors that may reduce bleeding while maintaining efficacy.
Do Factor XI/XIa inhibitors provide effective stroke prevention with improved safety compared to DOACs?
Comparison
FXI/XIa inhibitors vs standard of care anticoagulation
Design
Review
Authors
Loading...
May warrant phase 3 trials in AF if bleeding reductions hold; leaves open non-inferiority to DOACs.
Do Factor XI/XIa inhibitors provide effective stroke prevention with improved safety compared to DOACs?
Factor XI/XIa inhibitors are a promising novel class of anticoagulants that may reduce bleeding risks compared to current standard-of-care DOACs.
Gibson et al. (2025) conducted a review in Stroke prevention. Factor XI/XIa inhibitors vs. DOACs was evaluated. Factor XI/XIa inhibitors offer potential advantages over DOACs in stroke prevention, such as reduced bleeding and fewer drug interactions, though clinical trials must still demonstrate non-inferiority.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: